Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

被引：4
|
作者：
Richardson, Paul G. [1 ]
Htut, Myo [2 ]
Gasparetto, Cristina [3 ]
Zonder, Jeffrey A. [4 ]
Martin, Thomas G., III [5 ]
Chen, Janice [6 ]
Brooks, Christopher [6 ]
McDonald, Peter [6 ]
Rupprecht, Nicole [6 ]
Wysowskyj, Halyna [7 ]
Chauhan, Dharminder [8 ]
Ray, Arghya [8 ]
Anderson, Kenneth C. [9 ]
Paba-Prada, Claudia E. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] City Hope Natl Med Ctr, Judy & Bernard Briskin Ctr Multiple Myeloma Res, Duarte, CA USA
[3] Duke Univ, Med Ctr, Durham, NC USA
[4] Karmanos Canc Inst, Detroit, MI USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Stemline Therapeut, New York, NY USA
[7] Stemline Therapeut Inc, New York, NY USA
[8] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[9] Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-130410
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3145
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Htut, Myo
    Gasparetto, Cristina
    Zonder, Jeffrey
    Martin, Thomas G., III
    Scott, Emma C.
    Chen, Janice
    Shemesh, Shay
    Brooks, Christopher L.
    Chauhan, Dharminder
    Anderson, Kenneth C.
    Richardson, Paul G.
    Paba-Prada, Claudia E.
    [J]. BLOOD, 2016, 128 (22)
  • [2] Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
    Kumar, Sudhir
    Sharma, Atul
    Malik, Prabhat Singh
    Gogia, Ajay
    Pathak, Neha
    Sahoo, Ranjit Kumar
    Gupta, Ritu
    Prasad, Chandra Prakash
    Kumar, Lalit
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 288 - 297
  • [3] A phase 2 trial of leflunomide, pomalidomide, and dexamethasone for relapsed/refractory multiple myeloma
    Rosenzweig, Michael
    Sanchez, James
    Chowdhury, Arnab
    Nathwani, Nitya
    Janakiram, Murali
    Htut, Myo
    Sahebi, Firoozeh
    Walker, Tricia
    Pichiorri, Flavia
    Palmer, Joycelynne
    Krishnan, Amrita
    Keats, Jonathan
    Rosen, Steven
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S153 - S153
  • [4] Preliminary Results from a Phase Ib Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Richardson, Paul G.
    Mikhael, Joseph
    Usmani, Saad Z.
    Raje, Noopur
    Bensinger, William
    Campana, Frank
    Gao, Lei
    Dubin, Franck
    Wack, Claudine
    Anderson, Kenneth C.
    [J]. BLOOD, 2016, 128 (22)
  • [5] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Gasparetto, Cristina
    Bowles, Kristian M.
    Abdallah, Al-Ola
    Morris, Lura
    Mander, Gudrun
    Coppola, Sheryl
    Wang, Jing
    Ross, Jeremy A.
    Bueno, Orlando F.
    Arriola, Emma
    Mateos, Maria Victoria
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
  • [6] Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM)
    Badros, Ashraf Z.
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander M.
    Rapoport, Aaron P.
    Kocoglu, Mehmet H.
    Lederer, Emily
    Philip, Sunita
    Lesho, Patricia
    Johnson, Ashlee
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    [J]. BLOOD, 2016, 128 (22)
  • [7] A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Stampleman, Laura V.
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    [J]. BLOOD, 2014, 124 (21)
  • [8] Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma
    Mark, Tomer M.
    Forsberg, Peter A.
    Rossi, Adriana C.
    Pearse, Roger N.
    Pekle, Karen A.
    Perry, Arthur
    Boyer, Angelique
    Tegnestam, Linda
    Jayabalan, David
    Coleman, Morton
    Niesvizky, Ruben
    [J]. BLOOD ADVANCES, 2019, 3 (04) : 603 - 611
  • [9] Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
    Trudel, Suzanne
    Mccurdy, Arleigh
    Louzada, Martha L.
    Parkin, Stephen
    White, Darrell
    Chu, Michael P.
    Kotb, Rami
    Mian, Hira
    Othman, Ibraheem
    Su, Jiandong
    Khan, Aniba
    Gul, Engin
    Reece, Donna
    [J]. NATURE MEDICINE, 2024, 30 (03) : 543 - 551
  • [10] Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
    Matsue, Kosei
    Iwasaki, Hiromi
    Chou, Takaaki
    Tobinai, Kensei
    Sunami, Kazutaka
    Ogawa, Yoshiaki
    Kurihara, Mari
    Midorikawa, Shuichi
    Zaki, Mohamed
    Doerr, Thomas
    Iida, Shinsuke
    [J]. CANCER SCIENCE, 2015, 106 (11): : 1561 - 1567
12345